Page last updated: 2024-11-06

lesopitron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

lesopitron: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60813
CHEMBL ID2105051
SCHEMBL ID246589
MeSH IDM0203582

Synonyms (23)

Synonym
PDSP1_000055
lesopitron
PDSP2_000055
2-[4-[4-(4-chloropyrazol-1-yl)butyl]piperazin-1-yl]pyrimidine
L001393
132449-46-8
2-(4-(4-(4-chloropyrazol-1-yl)butyl)-1-piperazinyl)pyrimidine
h1cgm4755h ,
unii-h1cgm4755h
lesopitron [inn]
bdbm82365
cas_132449-46-8
nsc_60813
CHEMBL2105051
lesopitron [mi]
SCHEMBL246589
DB04970
2-{4- [4- (4-chloro-1-pyrazolyl)-butyl]-1-piperazinyl}pyrimidine
AHCPKWJUALHOPH-UHFFFAOYSA-N
DTXSID40157587
Q6531315
2-(4-(4-(4-chloro-1h-pyrazol-1-yl)butyl)piperazin-1-yl)pyrimidine
AKOS040747045

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Safety was assessed through physical examinations, monitoring of vital signs, 12-lead electrocardiograms, laboratory analyses, and adverse event monitoring."( Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.
Campbell, GM; Carter, FJ; Fresquet, A; Lloret, A; Marion-Landais, G; Murphy, MF; Sust, M, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability of lesopitron was about 10%, suggesting an important first-pass effect."( Absorption, distribution and excretion of [14C]-Lesopitron after single and repeated administration in rats and dogs.
Farran, R; García-Encina, G; García-Soret, A; Martínez, L; Moragon, T; Puig, S; Serafini, MT,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's10 (76.92)18.2507
2000's2 (15.38)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]